Analyst firms · Barclays · TMO

Barclays TMO price target and rating history

Thermo Fisher Scientific Inc (TMO) · Industrials

Barclays rates Thermo Fisher Scientific Inc (TMO) Overweight with a $550 price target, as of its latest action on Sep 11, 2025. It has published 4 rating actions on TMO since January 2022, including 1 upgrade and 1 downgrade. Across 12 firms with a TMO price target in the last 12 months, the median target is $635.

Current rating
Overweight
Price target
$550
Median target, all firms
$635
Actions on TMO
4

Barclays price target on TMO

$700$625$5502023202420252026
Barclays price target on TMO, each point a stated target, January 2022 to September 2025.

Every Barclays rating on TMO

How other firms rate TMO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$730Sep 9, 2026
CLSAOutperform$748Sep 3, 2026
BernsteinMkt Perform$520Jun 26, 2026
Piper SandlerNeutral$510Jun 11, 2026
HSBCHold$540Jun 3, 2026
Wolfe ResearchOutperform$535Jun 2, 2026
RBC Capital MarketsSector Perform$490May 15, 2026
DZ BankBuy$610Mar 27, 2026
CitigroupBuy$660Dec 11, 2025
Goldman SachsBuy$685Dec 9, 2025
KeyBanc Capital MarketsOverweight$750Dec 8, 2025
Morgan StanleyOverweight$670Dec 2, 2025

Questions about Barclays and TMO

What is Barclays's price target for TMO?
Barclays's latest stated price target for Thermo Fisher Scientific Inc (TMO) is $550, from its action on Sep 11, 2025.
What is Barclays's rating on TMO?
Barclays rates TMO Overweight, a bullish rating, as of Sep 11, 2025.
When did Barclays last change its view on TMO?
On Sep 11, 2025, Barclays upgrades to Overweight from Equal Weight, price target $550.
How does Barclays's TMO target compare with other analysts?
Across 12 firms with a TMO price target in the last 12 months, the median target is $635.

More TMO rating histories

All Barclays ratingsTMO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.